Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients who underwent low-fractionation curative radiation therapy and hormone therapy
Histopathologically confirmed prostate adenocarcinoma within 6 months of study enrollment
Patients with prostate cancer at high risk or above (c T3a-T4 or grade group 4-5 or PSA > 20 n g/mL) )
Patients who have undergone or are scheduled to undergo hormone therapy for high-risk prostate cancer
Adults over 20 years of age
prostate removal surgery, Patients with a history of lower pelvic surgery including rectal cancer surgery
primary cancer Patients with posterior extracapsular extension
Medically biodegradable substances such as bleeding predisposition Patients for whom infusion is not appropriate
Patients with a history of previous pelvic radiation therapy